Direct comparison of doses did not show evidence of dose dependence for blood pressure-lowering for any of the other thiazides for which RCT data were available : bendrofluazide , chlorthalidone , cyclopenthiazide , metolazone or indapamide .
This is based on an informal indirect comparison of results observed in other Cochrane review s on ACE inhibitors , ARBs and renin inhibitors compared with placebo , which used similar inclusion /exclusion criteria to the present review .Thiazides reduced potassium , increased uric acid and increased total cholesterol and triglycerides .
These effects were dose-related and were least for hydrochlorothiazide .
Chlorthalidone increased serum glucose but the evidence was unclear for other thiazides .
This systematic review shows that hydrochlorothiazide has a dose-related blood pressure-lowering effect .
Thiazides reduced potassium , increased uric acid and increased total cholesterol and triglycerides
BACKGROUND Hypertension is a modifiable cardiovascular risk factor .
Although it is established that low-dose thiazides reduce mortality as well as cardiovascular morbidity , the dose-related effect of thiazides in decreasing blood pressure has not been subject to a rigorous systematic review .
It is not known whether individual drugs within the thiazide diuretic class differ in their blood pressure-lowering effects and adverse effects .
OBJECTIVES To determine the dose-related decrease in systolic and /or diastolic blood pressure due to thiazide diuretics compared with placebo control in the treatment of patients with primary hypertension .
Secondary outcomes included the dose-related adverse events leading to patient withdrawal and adverse biochemical effects on serum potassium , uric acid , creatinine , glucose and lipids .
Low-dose bisoprolol/hydrochlorothiazide: an option in first-line, antihypertensive treatment.
Two recent , multicenter , double-blind , placebo-controlled studies established the efficacy and safety of low-dose bisoprolol/hydrochlorothiazide ( HCTZ ) in patients with mild to moderate essential hypertension .  Bisoprolol , a cardioselective beta-blocker , was used in a dose of 2.5 mg , 5 mg , or 10 mg . HCTZ was used at a dose of 6.25 mg . This low-dose compound was developed to minimize dose-related adverse effects . The addition of HCTZ to each of the doses of bisoprolol was compared with monotherapy and placebo . Results of both studies demonstrated that this once-a-day , low-dose option effectively reduced sitting diastolic and systolic blood pressure measured at the end of the 24-hour dosing period . Drug-related adverse effects , including those generally associated with traditional beta-blocker therapy , were infrequent in individuals who received the low-dose bisoprolol/HCTZ regimen . Dose-related side effects were minimized because of the low doses of the two agents used together . There were no significant changes in mean total cholesterol , triglycerides , or serum glucose with bisoprolol/HCTZ 6.25 mg therapy versus placebo ( analysis of variance statistical methods ) . The incidence of treatment-induced hypokalemia with bisoprolol/HCTZ 6.25 mg was not significant ; uric acid elevations were minimized , and the incidence of hyperuricemia was significantly ( P < 0.01 ) less with bisoprolol/HCTZ 6.25 mg than with 25 mg of HCTZ . Once-a-day dosing with the low-dose agent controlled ( defined as a sitting diastolic blood pressure < or = 90 mmHg and /or a decrease from baseline > or = 10 mmHg ) blood pressure in up to 80 % of patients for a full 24 hours after dosing . ( ABSTRACT TRUNCATED AT 250 WORDS
Direct comparison of doses did not show evidence of dose dependence for blood pressure-lowering for any of the other thiazides for which RCT data were available : bendrofluazide , chlorthalidone , cyclopenthiazide , metolazone or indapamide .
This is based on an informal indirect comparison of results observed in other Cochrane review s on ACE inhibitors , ARBs and renin inhibitors compared with placebo , which used similar inclusion /exclusion criteria to the present review .Thiazides reduced potassium , increased uric acid and increased total cholesterol and triglycerides .
These effects were dose-related and were least for hydrochlorothiazide .
Chlorthalidone increased serum glucose but the evidence was unclear for other thiazides .
This systematic review shows that hydrochlorothiazide has a dose-related blood pressure-lowering effect .
Thiazides reduced potassium , increased uric acid and increased total cholesterol and triglycerides
BACKGROUND Hypertension is a modifiable cardiovascular risk factor .
Although it is established that low-dose thiazides reduce mortality as well as cardiovascular morbidity , the dose-related effect of thiazides in decreasing blood pressure has not been subject to a rigorous systematic review .
It is not known whether individual drugs within the thiazide diuretic class differ in their blood pressure-lowering effects and adverse effects .
OBJECTIVES To determine the dose-related decrease in systolic and /or diastolic blood pressure due to thiazide diuretics compared with placebo control in the treatment of patients with primary hypertension .
Secondary outcomes included the dose-related adverse events leading to patient withdrawal and adverse biochemical effects on serum potassium , uric acid , creatinine , glucose and lipids .